These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 8140212)

  • 41. Wine and coronary heart disease.
    Barnard MJ; Linter SP
    Lancet; 1992 Aug; 340(8814):313-4. PubMed ID: 1353233
    [No Abstract]   [Full Text] [Related]  

  • 42. Aspirin and emboli.
    Cheng TO
    Lancet; 1981 Oct; 2(8250):809. PubMed ID: 6116933
    [No Abstract]   [Full Text] [Related]  

  • 43. Serge Renaud: from French paradox to Cretan miracle.
    Simini B
    Lancet; 2000 Jan; 355(9197):48. PubMed ID: 10615898
    [No Abstract]   [Full Text] [Related]  

  • 44. Chemotherapy in dental practice: aspirin compounds. II.
    Gurney BF
    Dent Dig; 1970 Nov; 76(11):476-82. PubMed ID: 5274157
    [No Abstract]   [Full Text] [Related]  

  • 45. Functional constituents of a local serotonergic system, intrinsic to the human coronary artery smooth muscle cells.
    Baskar K; Sur S; Selvaraj V; Agrawal DK
    Mol Biol Rep; 2015 Aug; 42(8):1295-307. PubMed ID: 25861735
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibition by combined therapy with ticlopidine and aspirin of enhanced platelet aggregation during physical exercise in patients with coronary artery disease.
    Kitai T; Nishikawa M; Tanigawa T; Okinaka T; Wada H; Shiku H; Ikeda Y; Ito M; Isaka N; Nakano T
    Am Heart J; 2001 Aug; 142(2):E1. PubMed ID: 11479480
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Aspirin and coronary artery diseases.
    Jauhari J
    J Indian Med Assoc; 1993 Mar; 91(3):50-1. PubMed ID: 8349998
    [No Abstract]   [Full Text] [Related]  

  • 48. The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease.
    Serebruany VL; Kogushi M; Dastros-Pitei D; Flather M; Bhatt DL
    Thromb Haemost; 2009 Jul; 102(1):111-9. PubMed ID: 19572075
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The possible role of serotonin 5HT2 receptor antagonism in cardioprotection.
    Noble MI; Drake-Holland AJ
    Neth J Med; 1992 Oct; 41(3-4):183-9. PubMed ID: 1470290
    [No Abstract]   [Full Text] [Related]  

  • 50. The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor.
    Gurbel PA
    Rev Cardiovasc Med; 2006; 7 Suppl 4():S20-8. PubMed ID: 17224887
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Optimizing platelet P2Y12 inhibition for patients undergoing PCI.
    Steinhubl S; Roe MT
    Cardiovasc Drug Rev; 2007; 25(2):188-203. PubMed ID: 17614940
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of serotonin 5HT2 receptor antagonism in the control of coronary artery disease.
    Noble MI; Drake-Holland AJ
    Q J Med; 1994 Jan; 87(1):11-6. PubMed ID: 8140212
    [No Abstract]   [Full Text] [Related]  

  • 53.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 54.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.